Emerging treatments for substance use and mental health disorders

Source: Pormezz/Shutterstock

The addiction treatment landscape is undergoing a fascinating transformation, with psychedelic therapies emerging as a promising frontier. This approach, once considered taboo, is gaining traction in scientific circles and shows potential for treating various substance use disorders. Understanding the nuances of this evolution is crucial to improving your treatment offering.

The revival of psychedelic research

After decades of prohibition, psychedelics are experiencing a research renaissance. Substances such as psilocybin (from “magic mushrooms”), MDMA, and ketamine are being studied for their therapeutic potential in the treatment of addiction, depression, and PTSD. For example, a recent review of randomized controlled trials found that psilocybin significantly reduced heavy drinking days for people with alcohol use disorders. Additionally, a 2017 study found that psychedelic use was associated with a 40% reduction in the risk of opioid misuse in the past year and a 27% reduction in the risk of opioid dependence in the year past among people with opiate use disorder.

How do psychedelics work?

Psychedelic-assisted treatment includes several stages: assessment and preparation, dosing and integration. During the preparation phase, patients learn about psychedelics and how they can facilitate healing.

Psychedelics are thought to work by:

1. Increased neuroplasticity (brain rewiring).

2. Alteration of ingrained thought patterns.

3. Facilitate emotional progress.

4. Enhance mindfulness and self-awareness.

A cautious approach to implementation is essential given the potential for “bad trips” or emotional distress. It is also vital to ensure informed consent, making clear the benefits and potential challenges associated with psychedelic treatments.

Navigating legal and ethical challenges

While the excitement surrounding psychedelics is palpable, there are legal hurdles. Currently, only states like Oregon and Colorado have legalized psychedelic therapy for mental health treatment, with an established licensing process. In other states, treatment facilities may explore partnerships with research organizations to participate in clinical trials.

Ethically, leaders must ensure that all patients feel safe and informed about their treatment options. Considerations about the cultural significance of these substances, particularly within indigenous communities, also deserve attention. It is critical that addiction treatment centers approach psychedelic use with respect for its cultural roots and aim to provide equitable access.

Integration of diversity and equity in health (DEIB) in psychedelic treatment

It is essential to ensure that psychedelic treatments are carried out in a manner informed by the DEIB. Here are some strategies to implement:

1. Culturally competent care: Train staff in cultural sensitivity to adequately address the different backgrounds of clients seeking psychedelic therapy.

2. Community involvement: Involve local communities in discussions about the introduction of psychedelic treatments, ensuring that their voices and concerns are heard.

3. Equitable access: Develop policies to provide these innovative treatments regardless of the client’s socio-economic status, thereby avoiding disparities in access.

4. Data transparency: Regularly assess patient demographics accessing psychedelic treatments to ensure equitable representation and adjust practices as necessary.

conclusion

As psychedelics are rediscovered as a potential treatment for addiction, those administering these medications in therapeutic settings must stay informed and prepared to adopt these innovations. By understanding the benefits, navigating the legal landscape, and committing to DEIB principles, addiction treatment centers can be at the forefront of this exciting new era in recovery. Embracing the potential of psychedelic-assisted therapies could transform the lives of countless people struggling with recovery, making it imperative that all leaders engage with these evolving treatment modalities.